|
MX9708620A
(es)
|
1995-05-10 |
1998-02-28 |
Pfizer |
Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
|
|
WO2001024785A2
(en)
|
1999-10-01 |
2001-04-12 |
Institute Of Molecular And Cell Biology |
Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
|
|
US6841561B1
(en)
|
1999-10-01 |
2005-01-11 |
Institute Of Molecular And Cell Biology |
Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
|
|
WO2003006424A1
(en)
|
2001-07-10 |
2003-01-23 |
4Sc Ag |
Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
|
|
US7652051B2
(en)
*
|
2004-08-25 |
2010-01-26 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
|
ATE474833T1
(de)
*
|
2004-09-22 |
2010-08-15 |
Janssen Pharmaceutica Nv |
Inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
JP2007015952A
(ja)
|
2005-07-06 |
2007-01-25 |
Shionogi & Co Ltd |
ナフタレン誘導体
|
|
DE102005049953A1
(de)
|
2005-10-19 |
2007-04-26 |
Sanofi-Aventis Deutschland Gmbh |
Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
|
|
WO2008028860A1
(en)
|
2006-09-08 |
2008-03-13 |
F. Hoffmann-La Roche Ag |
Benzotriazole kinase modulators
|
|
WO2010081898A1
(en)
|
2009-01-19 |
2010-07-22 |
Neurosearch A/S |
Novel benzotriazole derivatives useful for the treatment of cns disorders
|
|
EP2230232A1
(en)
|
2009-03-13 |
2010-09-22 |
Almirall, S.A. |
Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
|
|
EP2228367A1
(en)
|
2009-03-13 |
2010-09-15 |
Almirall, S.A. |
Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
|
|
US9316632B2
(en)
|
2009-03-17 |
2016-04-19 |
Marshall University Research Corporation |
Methods of screening chemotherapeutic agents and treating cancer
|
|
MY159575A
(en)
|
2009-04-02 |
2017-01-13 |
Merck Serono Sa |
Dihydroorotate dehydrogenase inhibitors
|
|
ES2642109T3
(es)
|
2009-12-09 |
2017-11-15 |
Agios Pharmaceuticals, Inc. |
Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
US9012464B2
(en)
|
2010-11-25 |
2015-04-21 |
Ratiopharm Gmbh |
Salts and polymorphic forms of Afatinib
|
|
WO2013049112A1
(en)
|
2011-09-27 |
2013-04-04 |
Emory University |
Detection of biomarkers using magnetic resonance
|
|
CN103965133B
(zh)
|
2013-01-31 |
2018-11-30 |
华东理工大学 |
一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
|
|
RS57962B1
(sr)
*
|
2013-02-25 |
2019-01-31 |
Aurigene Discovery Tech Ltd |
Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US11730716B2
(en)
|
2014-05-08 |
2023-08-22 |
Kiora Pharmaceuticals Gmbh |
Compounds for treating ophthalmic diseases and disorders
|
|
US11096934B2
(en)
|
2015-09-01 |
2021-08-24 |
The Broad Institute, Inc. |
Compounds and methods useful for treating or preventing hematological cancers
|
|
JP6961879B2
(ja)
|
2015-12-30 |
2021-11-05 |
レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ |
変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
|
|
JOP20190094A1
(ar)
|
2016-10-27 |
2019-04-25 |
Broad Inst Inc |
مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
|
|
WO2018136009A1
(en)
|
2017-01-20 |
2018-07-26 |
Aslan Pharmaceuticals Pte Ltd |
Combination therapy
|
|
US11311548B2
(en)
|
2017-03-02 |
2022-04-26 |
Aslan Pharmaceuticals Pte. Ltd. |
Cancer therapy
|
|
US20180369206A1
(en)
|
2017-04-24 |
2018-12-27 |
Aurigene Discovery Technologies Limited |
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
|
|
HRP20211462T1
(hr)
|
2017-04-24 |
2021-12-24 |
Aurigene Discovery Technologies Limited |
Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
TWI818954B
(zh)
|
2018-02-20 |
2023-10-21 |
法商施維雅藥廠 |
三取代之苯并三唑衍生物的使用方法
|
|
JP7126556B2
(ja)
|
2018-09-28 |
2022-08-26 |
富士フイルム株式会社 |
シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
|
|
WO2020109625A1
(en)
|
2018-11-30 |
2020-06-04 |
Fondazione Centro San Raffaele |
Combined treatment of primary central nervous system lymphoma
|
|
JOP20210147A1
(ar)
|
2018-12-21 |
2023-01-30 |
Les Laboratoires Servier Sas |
صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
|
|
US12582667B2
(en)
|
2019-09-27 |
2026-03-24 |
The Rockefeller University |
Compositions and methods to treat metastatic gastrointestinal cancer
|
|
CA3184024A1
(en)
|
2020-06-24 |
2021-12-30 |
Les Laboratoires Servier |
Use of a dhodh inhibitor compound in combination cancer therapy
|
|
WO2021262874A1
(en)
|
2020-06-24 |
2021-12-30 |
Servier Pharmaceuticals , Llc |
Use of a dhodh inhibitor compound in combination cancer therapy
|
|
ES3063941T3
(en)
|
2020-08-27 |
2026-04-21 |
Servier Lab |
Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
|